High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. (August 2017)
- Record Type:
- Journal Article
- Title:
- High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. (August 2017)
- Main Title:
- High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma
- Authors:
- Dlouhy, Ivan
Filella, Xavier
Rovira, Jordina
Magnano, Laura
Rivas-Delgado, Alfredo
Baumann, Tycho
Martínez-Trillos, Alejandra
Balagué, Olga
Martínez, Antonio
González-Farre, Blanca
Karube, Kennosuke
Gine, Eva
Delgado, Julio
Campo, Elías
López-Guillermo, Armando - Abstract:
- Highlights: High serum IL6, IL2-R or TNF levels were associated with shorter survival in DLBCL. Early death strongly correlated with elevated cytokines. Serum cytokines add further survival information along with RIPI score. Abstract: Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with heterogeneous outcomes. To improve accuracy of the international prognostic index score, new biological variables are being investigated. The aim of this study was to determine the prognostic significance of serum levels of different cytokines, namely soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF). We analyzed 197 de novo DLBCL patients (91 M/106 F; median age 66 years) treated with immunochemotherapy in a single institution. Serum cytokine determination was performed with ELISA, using the upper normal values as cut-offs. sIL-2R, IL-6 and TNF were elevated in 133, 130 and 144 cases, respectively. Elevation of each of these cytokines correlated with worse performance status, presence of B symptoms, advanced stage, elevated LDH and β2-microglobulin ( P < 0.03) and lower complete remission rate ( P < 0.001). Elevated levels of serum sIL-2R and TNF were significantly associated with shorter progression-free (PFS) and overall survival (OS), while elevated IL-6 only with shorter PFS. Early death (<4 months from diagnosis) strongly correlated with elevated cytokines. Determination of serum cytokines levels is simple and addsHighlights: High serum IL6, IL2-R or TNF levels were associated with shorter survival in DLBCL. Early death strongly correlated with elevated cytokines. Serum cytokines add further survival information along with RIPI score. Abstract: Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with heterogeneous outcomes. To improve accuracy of the international prognostic index score, new biological variables are being investigated. The aim of this study was to determine the prognostic significance of serum levels of different cytokines, namely soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF). We analyzed 197 de novo DLBCL patients (91 M/106 F; median age 66 years) treated with immunochemotherapy in a single institution. Serum cytokine determination was performed with ELISA, using the upper normal values as cut-offs. sIL-2R, IL-6 and TNF were elevated in 133, 130 and 144 cases, respectively. Elevation of each of these cytokines correlated with worse performance status, presence of B symptoms, advanced stage, elevated LDH and β2-microglobulin ( P < 0.03) and lower complete remission rate ( P < 0.001). Elevated levels of serum sIL-2R and TNF were significantly associated with shorter progression-free (PFS) and overall survival (OS), while elevated IL-6 only with shorter PFS. Early death (<4 months from diagnosis) strongly correlated with elevated cytokines. Determination of serum cytokines levels is simple and adds information regarding risk of early death, response to therapy, and outcome. … (more)
- Is Part Of:
- Leukemia research. Volume 59(2017:Aug.)
- Journal:
- Leukemia research
- Issue:
- Volume 59(2017:Aug.)
- Issue Display:
- Volume 59 (2017)
- Year:
- 2017
- Volume:
- 59
- Issue Sort Value:
- 2017-0059-0000-0000
- Page Start:
- 20
- Page End:
- 25
- Publication Date:
- 2017-08
- Subjects:
- Diffuse large B-cell lymphoma -- Cytokines -- Immunochemotherapy -- Outcome -- Toxicity
Leukemia -- Periodicals
Leukemia -- Periodicals
Leucémie -- Périodiques
Leukemia
Periodicals
Electronic journals
Electronic journals
616.9941905 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01452126 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.leukres.2017.05.014 ↗
- Languages:
- English
- ISSNs:
- 0145-2126
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5185.270000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4484.xml